Estrella Immunopharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ESLA Nasdaq 2834 www.estrellabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - Mar 5th, 2025 1:00 pm
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Feb 22nd, 2025 1:55 pm
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - Feb 21st, 2025 1:30 pm
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - Feb 19th, 2025 9:46 pm
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Nov 14th, 2024 8:05 pm
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells - Sep 27th, 2024 4:00 pm
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Aug 14th, 2024 4:00 pm